• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings.西南伦敦癌症网络的化疗引起的发热性中性粒细胞减少症的前瞻性研究。根据 NCAG/NCEPOD 的调查结果解释研究结果。
Br J Cancer. 2011 Feb 1;104(3):407-12. doi: 10.1038/sj.bjc.6606059. Epub 2010 Dec 21.
2
Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.晚期非小细胞肺癌一线化疗患者中性粒细胞减少相关费用
J Manag Care Pharm. 2009 Oct;15(8):669-82. doi: 10.18553/jmcp.2009.15.8.669.
3
A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study.一项用于预测化疗引起的发热性中性粒细胞减少风险的前瞻性验证列线图：一项多中心研究。
Support Care Cancer. 2015 Jun;23(6):1759-67. doi: 10.1007/s00520-014-2531-6. Epub 2014 Nov 30.
4
Management of febrile neutropenia in an acute oncology service.急性肿瘤科室中性粒细胞减少伴发热的管理
QJM. 2012 Apr;105(4):327-36. doi: 10.1093/qjmed/hcr217. Epub 2011 Nov 12.
5
History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis.无慢性共病史的癌症患者在未接受 G-CSF 预防治疗时发生化疗引起的发热性中性粒细胞减少症的风险。
Ann Oncol. 2014 Sep;25(9):1821-1829. doi: 10.1093/annonc/mdu203. Epub 2014 Jun 10.
6
Risk of repeated febrile episodes during chemotherapy-induced granulocytopenia in children with cancer: a prospective single center study.癌症患儿化疗引起粒细胞减少期间反复发热发作的风险：一项前瞻性单中心研究。
J Chemother. 2012 Jun;24(3):155-60. doi: 10.1179/1973947812Y.0000000002.
7
Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.低危发热性中性粒细胞减少症患者提前出院的安全性：一项多中心随机对照试验。
J Clin Oncol. 2011 Oct 20;29(30):3977-83. doi: 10.1200/JCO.2011.35.0884. Epub 2011 Sep 19.
8
Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.非髓性癌症化疗患者使用非格司亭与非格司亭生物类似药治疗的临床结局和发热性中性粒细胞减少相关成本比较。
J Manag Care Spec Pharm. 2018 Oct;24(10):976-984. doi: 10.18553/jmcp.2018.17447. Epub 2018 Apr 24.
9
Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.住院和门诊环境中化疗引起的发热性中性粒细胞减少症的发病率、治疗及后果。
J Oncol Pharm Pract. 2014 Jun;20(3):190-8. doi: 10.1177/1078155213492450. Epub 2013 Jul 2.
10
Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre.在英国一家地区癌症中心，接受常规护理的肿瘤患者中性粒细胞减少性发热的流行病学、管理和经济影响。
Ann Oncol. 2012 Jul;23(7):1889-93. doi: 10.1093/annonc/mdr520. Epub 2011 Nov 2.

引用本文的文献

1
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.癌症合并低危中性粒细胞减少症脓毒症患者早期从静脉抗生素治疗转换为口服抗生素治疗：EASI-SWITCH RCT。
Health Technol Assess. 2024 Mar;28(14):1-101. doi: 10.3310/RGTP7112.
2
Burden, risk factors, and management of neutropenic fever among solid cancer patients in Ethiopia.埃塞俄比亚实体癌患者中性粒细胞减少性发热的负担、危险因素及管理
SAGE Open Med. 2022 May 19;10:20503121221098236. doi: 10.1177/20503121221098236. eCollection 2022.
3
Incidence and clinical course of septic shock in neutropenic patients during chemotherapy for gynecological cancers.中性粒细胞减少症患者妇科癌症化疗期间脓毒性休克的发生率和临床病程。
J Gynecol Oncol. 2020 Sep;31(5):e62. doi: 10.3802/jgo.2020.31.e62.
4
The acute oncologist's role in managing patients with cancer and other comorbidities.急性肿瘤学家在管理患有癌症和其他合并症患者方面的作用。
J Comorb. 2012 Nov 5;2:10-17. doi: 10.15256/joc.2012.2.8. eCollection 2012.
5
Antiemetic and Myeloprotective Effects of in a Cisplatin-Induced Rat Model.[具体药物名称]在顺铂诱导的大鼠模型中的止吐和骨髓保护作用
Evid Based Complement Alternat Med. 2017;2017:9830342. doi: 10.1155/2017/9830342. Epub 2017 Feb 8.
6
The association of hyperglycemia and diabetes mellitus and the risk of chemotherapy-induced neutropenia among cancer patients: A systematic review with meta-analysis.癌症患者高血糖和糖尿病与化疗引起的中性粒细胞减少风险的关联：一项荟萃分析的系统评价
J Diabetes Complications. 2017 Jan;31(1):267-272. doi: 10.1016/j.jdiacomp.2016.09.006. Epub 2016 Sep 21.
7
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.转移性胰腺癌化疗方案的费用描述。
Med Oncol. 2016 May;33(5):48. doi: 10.1007/s12032-016-0762-8. Epub 2016 Apr 11.
8
Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.医生对于评估接受化疗且有中度发热性中性粒细胞减少风险的患者的风险以及使用粒细胞集落刺激因子作为一级预防措施的态度。
Med Oncol. 2015 Oct;32(10):236. doi: 10.1007/s12032-015-0682-z. Epub 2015 Aug 28.
9
Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.妇科恶性肿瘤患者化疗引起的中性粒细胞减少和发热性中性粒细胞减少。
Anticancer Drugs. 2015 Nov;26(10):1054-60. doi: 10.1097/CAD.0000000000000279.
10
Granulocyte colony-stimulating factor use in a large British hospital: comparison with published experience.英国一家大型医院中粒细胞集落刺激因子的使用情况：与已发表经验的比较。
Pharm Pract (Granada). 2010 Oct;8(4):213-9. doi: 10.4321/s1886-36552010000400002.

本文引用的文献

1
Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.《癌症相关感染的预防和治疗》，第 2.2016 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2016 Jul;14(7):882-913. doi: 10.6004/jnccn.2016.0093.
2
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.化疗的骨髓毒性和剂量强度：随机临床试验的报告实践。
J Natl Compr Canc Netw. 2003 Jul;1(3):440-54. doi: 10.6004/jnccn.2003.0038.
3
Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma.一项使用粒细胞集落刺激因子维持非霍奇金淋巴瘤化疗剂量强度的随机对照试验长期随访后的死亡率模式
Br J Cancer. 2008 Jul 22;99(2):253-8. doi: 10.1038/sj.bjc.6604468. Epub 2008 Jul 1.
4
Rational selection of patients for antibacterial prophylaxis after chemotherapy.化疗后抗菌药物预防性应用患者的合理选择。
J Clin Oncol. 2007 Oct 20;25(30):4821-8. doi: 10.1200/JCO.2006.08.7395.
5
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.粒细胞集落刺激因子一级预防对接受化疗的成年癌症患者发热性中性粒细胞减少症及死亡率的影响：一项系统评价
J Clin Oncol. 2007 Jul 20;25(21):3158-67. doi: 10.1200/JCO.2006.08.8823.
6
Myeloid growth factors. Clinical practice guidelines in oncology.髓系生长因子。肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2007 Feb;5(2):188-202. doi: 10.6004/jnccn.2007.0019.
7
Risk-adapted strategy for the management of febrile neutropenia in cancer patients.癌症患者发热性中性粒细胞减少症管理的风险适应性策略
Support Care Cancer. 2007 May;15(5):477-82. doi: 10.1007/s00520-006-0185-8. Epub 2007 Feb 9.
8
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.欧洲癌症研究与治疗组织（EORTC）关于使用粒细胞集落刺激因子降低淋巴瘤和实体瘤成年患者化疗引起的发热性中性粒细胞减少症发生率的指南。
Eur J Cancer. 2006 Oct;42(15):2433-53. doi: 10.1016/j.ejca.2006.05.002. Epub 2006 Jun 5.
9
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.白细胞生长因子使用建议的2006年更新：基于证据的临床实践指南
J Clin Oncol. 2006 Jul 1;24(19):3187-205. doi: 10.1200/JCO.2006.06.4451. Epub 2006 May 8.
10
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.成年癌症患者发热性中性粒细胞减少症相关的死亡率、发病率和成本
Cancer. 2006 May 15;106(10):2258-66. doi: 10.1002/cncr.21847.

西南伦敦癌症网络的化疗引起的发热性中性粒细胞减少症的前瞻性研究。根据 NCAG/NCEPOD 的调查结果解释研究结果。

A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings.

机构信息

Department of Medical Oncology, Guy's & St Thomas' NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK.

出版信息

Br J Cancer. 2011 Feb 1;104(3):407-12. doi: 10.1038/sj.bjc.6606059. Epub 2010 Dec 21.

DOI:10.1038/sj.bjc.6606059
PMID:21179036
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3049562/
Abstract

BACKGROUND

Chemotherapy-induced febrile neutropenia is a medical emergency complicating the treatment of many cancer patients. It is associated with considerable morbidity and mortality, as well as impacting on healthcare resources.

METHODS

A prospective study of all cases of chemotherapy-induced febrile neutropenia in the South West London Cancer Network was conducted over a 4-month period. Factors including demographics, treatment history, management of febrile neutropenia and outcome were recorded.

RESULTS AND CONCLUSION

Our results reflect those of the recent National Chemotherapy Advisory Group (NCEPOD, 2008)/National Confidential Enquiry into Patient Outcomes and Death reports (NCAG, 2009) and highlight the need for network-wide clinical care pathways to improve outcomes in this area.

摘要

背景

化疗引起的发热性中性粒细胞减少症是一种医疗急症，使许多癌症患者的治疗复杂化。它与相当大的发病率和死亡率有关，也会影响医疗资源。

方法

在西南伦敦癌症网络中，对所有化疗引起的发热性中性粒细胞减少症病例进行了为期 4 个月的前瞻性研究。记录了人口统计学、治疗史、发热性中性粒细胞减少症的处理和结果等因素。

结果和结论

我们的结果反映了最近的国家化疗咨询组（NCEPOD，2008 年）/国家患者结局和死亡机密调查（NCAG，2009 年）的结果，并强调需要在整个网络范围内制定临床护理路径，以改善该领域的结局。